San Diego, CA, March 29, 2022 (GLOBE NEWSWIRE) – via New Media Wire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States to launch the first cannabis-derived products, brands, and supply chain, announced today that it has issued a letter to shareholders, providing comments on the company’s recent financial and operating results and goals. coming. Please see the contents of the message below.
For those of you who don’t know me, I’m the newly appointed CEO of Medical Marijuana, Inc. I am pleased to take the helm of Medical Marijuana, Inc. and help us advance our mission of becoming the world’s first truly global cannabis company.
I joined Medical Marijuana, Inc. In 2016, a pivotal time for positive legislation and changes in the cannabis industry. Since then, she has led the company in several executive roles. I am proud to lead the company’s phenomenal sales growth and lead the company in its international expansion. International growth is one of the biggest opportunities for Medical Marijuana, Inc. Although there are many challenges that accompany setting up operations around the world, due to the different cannabis legislation in each country, we are committed to making sure that everyone has free, safe and legal access to cannabis no matter where you live.
Over the past few years, we’ve seen a massive shift in both the recognition and demand for hemp-based products. We’ve contributed significantly to this transformation through tough legislative battles, personal testimonies, product innovations, and research. We are proud to be the first cannabis company to submit to the World Health Organization regarding the safety and efficacy of non-psychoactive hemp-based products, as well as to the Federal Drug Administration in conjunction with the passage of the Farm Act. We’ve created an industry that is not only legitimate and revenue-generating, but one that makes a difference in the lives of many, every day. However, there is still much work to be done. It’s hard to believe that cannabis is still a scheduled substance, even in its non-psychoactive form, in much of the world. We intend to be a huge part of the force that is changing that.
As you might imagine, Medical Marijuana, Inc. It has also grown over the years. We have made great strides in setting industry standards for product quality and safety and are constantly looking for new ways to innovate and generate value. We have also invested in our own infrastructure. We were excited to announce in 2021 that we now manufacture nearly 100% of our merchandise internally. In addition, we now have offices in the United States, Mexico, Brazil, Europe, Japan, and most recently, South Africa. We are in a better position than ever to expand production as we continue to grow and expand our operations into many new global markets.
As we have announced throughout this year, our international business segments continue to achieve impressive growth. We are very proud of our teams in Europe, Latin America, Asia and South Africa, for their hard work in collaborating with local and regional regulators to meet all safety and legal requirements to give our group of companies a physical presence in these regions. In fact, our branch CEO HempMeds®, Mr. Raul Elizalde has been recognized Washington Post, as well as several other noteworthy publications, on the opportunity that Latin America represents and how MJNA companies have a first-mover advantage in the region. Benzinga also acknowledged our expansion in Poland And the South Africa And Network Magazine praised our entry as one of the first companies in Hong Kong market. We believe that the Asian market is one of the largest growth opportunities globally, and we are well positioned to take advantage of it, bringing legal cannabis-based products to the region for the first time in recent history. After analyzing the changing public and government perception of cannabis, we believe that the world’s next green rush may occur in Africa. Although we are only getting started recently, we have created momentum in South Africa and look forward to helping create positive change and ensuring free legal access across the region.
While we continue to expand globally with our non-psychoactive product lines continue to be an area where we see growth opportunities, we have always been a pioneer and leader. Firsts® Company. The company’s major focus is on continuing our legacy of industry leadership. For example, while psychoactive cannabis remains illegal at the federal level, we expect this to change in the coming years. Since our company is traded on US stock exchanges, we have not been able to participate in this sector of the industry yet; However, we are taking steps to position ourselves to move quickly as it enters, should the regulatory framework change. We were the first cannabis company to be publicly traded in the United States and we have no intention of not taking advantage of this position in both the medical and ultimately, recreational markets.
New hemp-derived products are now incredibly popular in the United States and will become so worldwide. We recently launched into space with a Delta-8 that is 100% legal Hemp Farm Bill. We expect continued growth in this emerging space.
In addition to the nutritional supplement market, we also anticipate that the pharmaceutical industry will provide growth for Medical Marijuana, Inc. We have invested heavily in the space for many years now, with AXIM Biotechnologies (OTC: AXIM) and Neuropathix (OTC: NPTX) as our valuable investments. AXIM has evolved into a testing and diagnostics company for a variety of conditions such as Dry Eye Disease and we believe its technology will provide significant advances to the medical community. We have seen how important diagnoses are to our daily lives over the past two years during the COVID-19 pandemic. Neuropathix has developed KLS-13019, a patented non-opioid monotherapy derivative of cannabis that has been identified as a primary clinical target for the potential treatment of a range of neurodegenerative and neurodegenerative disorders. Neuropathix has just received a grant notice for a $2.79 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) for developmental advances for KLS-13019. We see great value in providing a solution to neuropathic pain.
Medical Marijuana, Inc. Also developing its own pharmaceutical legacy. We have hired teams in Brazil and Mexico to develop pharmaceutical solutions for our clients and we are making significant progress in making this a reality. We look forward to providing more updates on this soon. Finding pharmaceutical solutions is not an easy task; However, we have no doubts about the potential of cannabis-containing medications through a variety of healthcare and we intend you to be a big part of it.
While we believe that innovation and further expansion are the core of our long-term success, we also understand that our bottom line is of paramount importance to our shareholders. We believe that building the foundations of the company further is the way to unlock shareholder value. This includes eliminating debt, reducing cost, and implementing systems that will generate profit and value. As mentioned last year, we have implemented a world-class ERP system which will enable us to meet audit requirements in the future.
I am very pleased to share that we have worked hard to remove the old long-term convertible debt. This should relieve additional selling pressure, which is a huge win for a base of ardent supporters of our company.
In conclusion, I hope this letter has provided a glimpse into the bright future that Medical Marijuana, Inc. And to share with me the excitement of our vision. We strive to be on our way to being the first truly global cannabis company and will continue to innovate and lead the field. We strive to do so in a financially sound, socially responsible manner and always with our customers, team members and stakeholders in mind. This is my commitment to you as we move forward to build a world of cannabis and cannabis in every home.
CEO, Medical Marijuana, Inc. (OTC: MJNA)
About Medical Marijuana, Inc.
We are Firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabis space: a global group of cannabis-based food brands led by Kannawi® And the HempMeds®; A leader in sourcing high-quality, legal, non-psychoactive cannabis products derived from industrial hemp; and the sector of cannabis-based clinical research and development of botanical medicines led by pharmaceutical investment firms and partners including AXIM® Biotechnologies, Inc. And the Neuropathics. Medical Marijuana, Inc. As the best CBD product ever CNBC. Medical Marijuana, Inc. Also the first company to obtain historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a pioneer in developing international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in. in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To watch a video of Medical Marijuana, Inc. , click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor law created by those sections. This material contains statements about expected future events and/or financial results of a forward-looking nature and subject to risks and uncertainties. These forward-looking statements by definition include risks, uncertainties and other factors, which could cause Medical Marijuana, Inc.’s actual results, performance or achievements to differ. materially from the data contained herein.
Disclosure by the Food and Drug Administration (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not. Selling or distributing any products that violate the Controlled Substances Act in the United States.
Public Relations Contact:
Investor Relations Contact:
p. (858) 283-4016